Tempest reports FY2023 net loss $29.5M; positive Phase 1b/2 HCC data for TPST-1120

Tempest Therapeutics, Inc.

Net loss $29.5M ($1.91/sh) vs $35.7M in 2022; cash $39.2M, runway into Q2 2025.
TPST-1120 triplet arm: 30% cORR vs 13.3% control; OS HR 0.59 favoring TPST-1120 in first-line HCC.
Plan to advance TPST-1120 into pivotal Phase 3 in HCC; TPST-1495 into Phase 2 FAP (pending NCI).
R&D expenses down to $17.5M from $22.5M, primarily due to lower CRO costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tempest Therapeutics, Inc. reported financial results for year ended December 31, 2023.

Period: year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 19, 2024, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023 and other business highlights.

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-033464

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.